Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Denali Therapeutics Inc (NQ: DNLI)
25.93 USD  -1.07 (-3.96%)
Official Closing Price  /  Updated: 4:55 PM EDT, Jun 5, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 471,900
Open 27.56
Bid (Size) 18.00 (2)
Ask (Size) 30.00 (1)
Prev. Close 27.00
Today's Range 25.84 - 27.86
52wk Range 12.39 - 30.41
Shares Outstanding 94,441,892
Dividend Yield N/A
Performance
YTD
+58.21%
+58.21%
1 Month
+2.61%
+2.61%
3 Month
+42.63%
+42.63%
6 Month
+42.00%
+42.00%
1 Year
+40.16%
+40.16%
Top News
More News
Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity
Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly... Read More
from PR Newswire
Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine
from GlobeNewswire News Releases
More News
Read More
Denali Therapeutics Reports First Quarter 2020 Financial Results and Provides COVID-19 Response Update
from GlobeNewswire News Releases
Denali Therapeutics Provides Pipeline and Business Update in Response to the COVID-19 Pandemic
from GlobeNewswire News Releases
Flagship Pioneering Completes Raising a New $1.1 Billion Capital Pool
from PR Newswire
Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
from GlobeNewswire News Releases
Repertoire Immune Medicines Launches Type 1 Diabetes Focused Program with Investment from JDRF T1D Fund
from Business Wire News Releases
Denali Therapeutics Reaches Analyst Target Price
category ETFs
from ETF Channel
Denali Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
from GlobeNewswire News Releases
Flagship Pioneering Announces the Launch of Repertoire Immune Medicines with Industry Veteran John G. Cox as Chief Executive Officer
from Business Wire News Releases
First Week of July 17th Options Trading For Denali Therapeutics (DNLI)
category Stocks
from Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.